# Treatment of Orthostatic Hypotension

> **NCT00581477** · PHASE2,PHASE3 · TERMINATED · sponsor: **Vanderbilt University** · enrollment: 8 (actual)

## Conditions studied

- Autonomic Nervous System Diseases
- Orthostatic Hypotension
- Dopamine Beta-Hydroxylase Deficiency
- Orthostatic Intolerance

## Interventions

- **DRUG:** Droxidopa Oral Product

## Key facts

- **NCT ID:** NCT00581477
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** 1\. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt.
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581477, "Treatment of Orthostatic Hypotension". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00581477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*